These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31287788)

  • 1. Prediction of Biopharmaceutical Drug Disposition Classification System (BDDCS) by Structural Parameters.
    Golfar Y; Shayanfar A
    J Pharm Pharm Sci; 2019; 22(1):247-269. PubMed ID: 31287788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neural Network Models for Predicting Solubility and Metabolism Class of Drugs in the Biopharmaceutics Drug Disposition Classification System (BDDCS).
    Ashrafi A; Teimouri K; Aghazadeh F; Shayanfar A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):1-6. PubMed ID: 37864650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BDDCS class prediction for new molecular entities.
    Broccatelli F; Cruciani G; Benet LZ; Oprea TI
    Mol Pharm; 2012 Mar; 9(3):570-80. PubMed ID: 22224483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs.
    Hosey CM; Chan R; Benet LZ
    AAPS J; 2016 Jan; 18(1):251-60. PubMed ID: 26589308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BDDCS applied to over 900 drugs.
    Benet LZ; Broccatelli F; Oprea TI
    AAPS J; 2011 Dec; 13(4):519-47. PubMed ID: 21818695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References.
    Bocci G; Oprea TI; Benet LZ
    AAPS J; 2022 Feb; 24(2):37. PubMed ID: 35199251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS).
    Li J; Larregieu CA; Benet LZ
    Chin J Nat Med; 2016 Dec; 14(12):888-897. PubMed ID: 28262115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
    Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
    Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
    Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
    J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines.
    Charalabidis A; Sfouni M; Bergström C; Macheras P
    Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number.
    Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ
    Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.
    Benet LZ
    J Pharm Sci; 2013 Jan; 102(1):34-42. PubMed ID: 23147500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts.
    Camenisch GP
    Pharm Res; 2016 Nov; 33(11):2583-93. PubMed ID: 27439505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational models to assign biopharmaceutics drug disposition classification from molecular structure.
    Khandelwal A; Bahadduri PM; Chang C; Polli JE; Swaan PW; Ekins S
    Pharm Res; 2007 Dec; 24(12):2249-62. PubMed ID: 17846869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System.
    Benet LZ
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):162-7. PubMed ID: 20002064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system.
    Wu CY; Benet LZ
    Pharm Res; 2005 Jan; 22(1):11-23. PubMed ID: 15771225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS.
    Garrison KL; Sahin S; Benet LZ
    J Pharm Sci; 2015 Sep; 104(9):3229-35. PubMed ID: 26010239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
    Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
    Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data.
    Heimbach T; Xia B; Lin TH; He H
    AAPS J; 2013 Jan; 15(1):143-58. PubMed ID: 23139017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel high/low solubility classification methods for new molecular entities.
    Dave RA; Morris ME
    Int J Pharm; 2016 Sep; 511(1):111-126. PubMed ID: 27349790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.